Have a feature idea you'd love to see implemented?
Let us know!
BLUE bluebird bio Inc
Price (delayed)
$0.2979
Market cap
$57.92M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.87
Enterprise value
$352.3M
bluebird bio, Inc., based in Cambridge, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders and cancer. The company's only - in the European Union -
Highlights
The EPS has increased by 21% since the previous quarter
The company's net income rose by 8% QoQ
The revenue has surged by 144% year-on-year but it has declined by 3.2% since the previous quarter
bluebird bio's debt has increased by 20% YoY but it has decreased by 7% from the previous quarter
bluebird bio's equity has plunged by 111% from the previous quarter and by 103% YoY
The quick ratio has plunged by 76% YoY and by 44% from the previous quarter
Key stats
What are the main financial stats of BLUE
Market
Valuations
Earnings
Shares outstanding
194.44M
Market cap
$57.92M
Enterprise value
$352.3M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.63
Revenue
$53.12M
EBIT
-$260.2M
EBITDA
-$139.68M
Free cash flow
-$227.02M
Per share
Balance sheet
Liquidity
EPS
-$1.87
Free cash flow per share
-$1.17
Book value per share
-$0.03
Revenue per share
$0.27
TBVPS
$2.32
Total assets
$465.06M
Total liabilities
$470.84M
Debt
$365.02M
Equity
-$5.79M
Working capital
-$145.22M
Debt to equity
-63.09
Current ratio
0.51
Quick ratio
0.3
Net debt/EBITDA
-2.11
Margins
Efficiency
Dividend
EBITDA margin
-262.9%
Gross margin
-43.5%
Net margin
-565.7%
Operating margin
-596.2%
Return on assets
-53.2%
Return on equity
-322.5%
Return on invested capital
-53.1%
Return on capital employed
-153.9%
Return on sales
-489.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BLUE stock price
How has the bluebird bio stock price performed over time
Intraday
-1.68%
1 week
-17.84%
1 month
-40.04%
1 year
-91.86%
YTD
-78.41%
QTD
-42.66%
Financial performance
How have bluebird bio's revenue and profit performed over time
Revenue
$53.12M
Gross profit
-$23.1M
Operating income
-$316.68M
Net income
-$300.52M
Gross margin
-43.5%
Net margin
-565.7%
The revenue has surged by 144% year-on-year but it has declined by 3.2% since the previous quarter
bluebird bio's net margin has plunged by 96% YoY but it has increased by 5% from the previous quarter
BLUE's operating margin is down by 37% year-on-year but it is up by 5% since the previous quarter
The gross margin has contracted by 28% from the previous quarter
Growth
What is bluebird bio's growth rate over time
Valuation
What is bluebird bio stock price valuation
P/E
N/A
P/B
N/A
P/S
1.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.63
The EPS has increased by 21% since the previous quarter
bluebird bio's equity has plunged by 111% from the previous quarter and by 103% YoY
The revenue has surged by 144% year-on-year but it has declined by 3.2% since the previous quarter
BLUE's P/S is 73% below its last 4 quarters average of 4.0
Efficiency
How efficient is bluebird bio business performance
The return on sales has dropped by 146% year-on-year but it has increased by 7% since the previous quarter
bluebird bio's ROE has decreased by 48% from the previous quarter
bluebird bio's return on invested capital has increased by 3.5% QoQ
bluebird bio's ROA has increased by 2% from the previous quarter
Dividends
What is BLUE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BLUE.
Financial health
How did bluebird bio financials performed over time
The quick ratio has plunged by 76% YoY and by 44% from the previous quarter
The current ratio has plunged by 67% YoY and by 25% from the previous quarter
bluebird bio's equity has plunged by 111% from the previous quarter and by 103% YoY
bluebird bio's debt has increased by 20% YoY but it has decreased by 7% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.